liver metastatic breast cancer
Conditions
Interventions
Patients start with their newly selected chemotherapy. If no extra-hepatic
tumour progression is seen after their chemotherapy evaluation of the newly
selected therapy, she can be screened for inclu
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Women >18 years • Patients with hormone positive and HER2 negative liver dominant metastatic breast cancer • No extra-hepatic disease progression at the evaluation of at least second line systemic chemotherapy • Suitable for TARE evaluated after the mapping angiography • Measurable target tumors in the liver according to RECIST 1.1 • Liver tumor burden 1000/µL; thrombocyte count >1000000 µL; eGFR >45/mL/min/1.73 m2; albumin > 3.0 g/dl, bilirubin
Exclusion criteria
Exclusion criteria: • Life expectancy 50Gy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We expect that this treatment strategy of TARE and systemic chemotherapy is feasible if 85% of the included patients safely received the combination therapy. Safety is defined as the percentage of the 90 day post-radioembolization toxicity (CTCAE/SIR grade 3 or higher) which leads to discontinuation of the current systemic chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will collect data that might be associated with lesion- and patient-based response, overall toxicity and quality of life. These data can be used to improved future study protocols. | — |
Countries
Netherlands
Outcome results
None listed